Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Company Description (as filed with the SEC)
We are a clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for diseases where there are significant unmet medical needs. We are developing a robust and growing portfolio of novel product candidates generated by Contour®, our proprietary structure-based drug discovery platform. Our most advanced wholly owned product candidate is VTP-43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. In 2015, we completed two Phase 1 studies with VTP-43742 and expect to announce top-line results from a Phase 2a proof-of-concept clinical trial by the end of the first quarter of 2016. VTP-38543, our second product candidate is in a Phase 2a proof-of-concept clinical trial for the treatment of atopic dermatitis with trial results expected in the second half of 2016. ... More ...
Where does VTAE fit in the risk graph?
|Annual EPS Est:||$-2.03|
|Quarterly EPS Est:||-0.42|